Press Releases
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings
End-to-end solution accelerates clinical trials with speed, convenience and quality
Thermo Fisher Scientific’s expanded Direct-to-Patient services build on its global Clinical Site-to-Patient program that launched earlier this year to ensure clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic. The program can support any trial phase and a range of trial variables including Interactive Response Technology (IRT) systems, blinded/unblinded and home nursing providers. Clinical Site-to-Patient services are available in 47 countries and have supported more than 1,500 shipments to patients worldwide to help treat more than 25 different indications.